Compare Hewlett Packard Enterprise Co (HPE) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hewlett Packard Enterprise Co vs Vertex Pharmaceuticals Incorporated — how do they compare? Hewlett Packard Enterprise Co trades at $73.59 (market cap $94.25B), while Vertex Pharmaceuticals Incorporated trades at $509.5 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Hewlett Packard Enterprise Co pays a 0.8% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hewlett Packard Enterprise Co for 33 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| HPE | VRTX | |
|---|---|---|
Market Cap | $94.25B | $127.55B |
Volume | 16,060,854 | 1,487,944 |
Sector | Technology | Health |
52-Week High | $72.12 | $557.96 |
52-Week Low | $20.01 | $407.37 |
Typical Hold Time | 33 Days | 120 Days |
Enterprise Value | $108.28B | $121.68B |
Dividend Yield | 0.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPE trades at $73.46, up 1.87% today and near its 52-week high, driven by strong AI infrastructure demand. The stock has a bullish technical signal with moving averages supporting the uptrend. Recent earnings beats, including Q2 2026 EPS of $1.11 versus $0.932 expected, highlight operational strength. A $1.2 billion AI server order from Vultr and raised revenue guidance fuel optimism, though valuation ratios like a P/E of 36.6 suggest premium pricing.
Outlook remains positive with AI-driven growth catalysts, but risks include high valuation and competitive pressures. Analyst consensus is mixed with a $70.35 price target, slightly below current levels. Net income margin compression in 2025 to 0.16% warrants monitoring, though 2026 projections show recovery. The stock's momentum hinges on execution of AI orders and margin expansion.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hewlett Packard Enterprise Co
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
